Colorectal Cancer Diagnosis and Therapeutics Market Trends, Size, Competitive Analysis and Forecast 2021-2027

The global colorectal cancer diagnosis and treatment market is anticipated to grow at a CAGR of 4.3% during the forecast period (2021-2027). The rising change in lifestyle of people such as lack of physical activity, consumption of alcohol and tobacco, smoking, and inadequate diet, rising prevalence of colorectal cancer cases, increasing awareness for the treatment of cancer, rising FDA approvals, and increasing geriatric population is driving the colorectal cancer diagnosis and treatment market during the forecast period. For instance, as per the United Nations, in 2019 the population with an age of 65 years or above was 9% across the globe. Besides, colorectal cancer is one of the most occurring cases in the human. As per the American cancer society, around 104,270 new cases of colon cancer are expected in the US in 2021.

To Request a Sample of our Report on Colorectal Cancer Diagnosis and Therapeutics Market: https://www.omrglobal.com/request-sample/colorectal-cancer-therapeutics-market

Besides, in May 2020, Eli Lilly and Company, has announced that the US Food and Drug Administration (FDA) has approved CYRAMZA, a ramucirumab injection, in combination with FOLFIRI (irinotecan, folinic acid, and fluorouracil), for the treatment of patients with metastatic colorectal cancer (mCRC) with highly progressed or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. In July 2020, Taiho Pharmaceutical Co., Ltd. has launched its anticancer agent LONSURF for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.

Additionally, in May 2019, EDP Biotech Corporation has announced an agreement with Luminex Corp. to sell a blood-based colorectal cancer diagnostic assay of Luminex’s technology, named ColoPlex. In September 2019, Prescient Metabiomics has announced that the US food and Drug Administration (FDA) has approved the device LifeKit to prevent colorectal neoplasia tests. This device is first made for a non-invasive diagnostic test, which is designed to detect pre-cancerous polyps as well as early-stage carcinomas, with the potential for the prevention of colorectal cancer. However, the demand for the treatment of cancers, new drugs, FDA approvals, and device launches, and the increasing prevalence of cancer patients could impede the global colorectal cancer diagnosis and treatment market over the coming years.

Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027

Segment Covered-
• By Type
• By Diagnosis
• By Treatment
• By End-User

Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape- Abbott Diagnostics, Bayer AG, Boehringer Ingelheim, Beckman Coulter, F.Hoffmann-La Roche Ltd, Quest Diagnostics Inc., among others

(Get 15% Discount on Buying this Report)
A full Report of Colorectal Cancer Diagnosis and Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/colorectal-cancer-therapeutics-market

Global Colorectal Cancer Diagnosis and Treatment Market Report Segment

By Type
• Adenocarcinomas
• Carcinoid Tumors
• Lymphomas
• Sarcomas
• Gastrointestinal Stromal Tumors (GISTS)

By Diagnosis
• Digital Rectal Examination
• Fecal Occult Blood Test
• Flexible Sigmoidoscopy
• Colonoscopy
• Others (Biopsy)

By Treatment
• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy

By End-User
• Multispecialty Hospitals
• Cancer Research Centers

Global Colorectal Cancer Diagnosis and Treatment Market Report Segment by Region

North America
• US
• Canada

Europe
• Germany
• United Kingdom
• France
• Spain
• Italy
Rest of Europe

Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America

Company Profiles
• Abbott Laboratories
• Bayer AG
• Beckman Coulter, Inc.
• Boehringer Ingelheim International GmbH
• Clinical Genomics Technologies Pvt. Ltd.
• EDP Biotech Corp.
• Epigenomics AG
• Eli Lilly and Co.
• Exact Sciences Corp.
• Genomictree Co., Ltd.
• IMV Inc.
• ISA Pharmaceuticals B.V.
• Merck & Co., Inc.
• Metabiomics Corp.
• Quest Diagnostics Inc.,
• Randox Laboratories Ltd
• F.Hoffmann-La Roche Ltd
• Siemens Healthcare Pvt. Ltd.
• Taiho Pharmaceutical Co., Ltd.

• VolitionRX Ltd.
Reasons for Buying from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/colorectal-cancer-therapeutics-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.